Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Delayed Repolarization Caused by hERG Block With Different Drug Modalities Can Be Detected in Stem Cell-Derived Cardiomyocytes: Incubation Time Matters.
Journal: Clinical and translational science
Published: March 04, 2025
Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions.
Journal: Journal of pharmacological and toxicological methods
Published: May 16, 2024
Scientific Review of the Proarrhythmic Risks of Oligonucleotide Therapeutics: Are Dedicated ICH S7B/E14 Studies Needed for Low-Risk Modalities?
Journal: Clinical pharmacology and therapeutics
Published: November 07, 2023
Assessment of sarcomere shortening and calcium transient in primary human and dog ventricular myocytes.
Journal: Journal of pharmacological and toxicological methods
Published: March 23, 2023
Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in hERG Assays.
Journal: Nucleic acid therapeutics
Published: December 28, 2022
Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma.
Journal: Journal of gastrointestinal oncology
Published: September 18, 2022
Validation of using cardioplegic solutions for preserving cardiac function in isolated rabbit heart assays.
Journal: Journal of pharmacological and toxicological methods
Published: February 01, 2021
Comprehensive in vitro pro-arrhythmic assays demonstrate that omecamtiv mecarbil has low pro-arrhythmic risk.
Journal: Clinical and translational science
Published: January 14, 2021
Effects of omecamtiv mecarbil on calcium-transients and contractility in a translational canine myocyte model.
Journal: Pharmacology research & perspectives
Published: June 30, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
Journal: Clinical pharmacology and therapeutics
Published: June 02, 2020
Inotropic assessment in engineered 3D cardiac tissues using human induced pluripotent stem cell-derived cardiomyocytes in the BiowireTM II platform.
Journal: Journal of pharmacological and toxicological methods
Published: February 20, 2020
Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture.
Journal: Regulatory toxicology and pharmacology : RTP
Published: February 18, 2020
Last Updated: 09/26/2026